{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(8)"],"submitter":["Biggs CN"],"pubmed_abstract":["<h4>Background</h4>Extracellular vesicles released by prostate cancer present in seminal fluid, urine, and blood may represent a non-invasive means to identify and prioritize patients with intermediate risk and high risk of prostate cancer. We hypothesize that enumeration of circulating prostate microparticles (PMPs), a type of extracellular vesicle (EV), can identify patients with Gleason Score≥4+4 prostate cancer (PCa) in a manner independent of PSA.<h4>Patients and methods</h4>Plasmas from healthy volunteers, benign prostatic hyperplasia patients, and PCa patients with various Gleason score patterns were analyzed for PMPs. We used nanoscale flow cytometry to enumerate PMPs which were defined as submicron events (100-1000nm) immunoreactive to anti-PSMA mAb when compared to isotype contro"],"journal":["Oncotarget"],"pagination":["8839-49"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4891008"],"repository":["biostudies-literature"],"pubmed_title":["Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry."],"pmcid":["PMC4891008"],"pubmed_authors":["Biggs CN","Yang J","Pardhan S","Brett SI","Wolf P","Chambers AF","Townson JL","Izawa JI","Siddiqui KM","MacMillan CD","Leong HS","Chin JL","Durfee PN","Guo QQ","Power NE","Al-Zahrani AA","Fleshner NE","Brinker JC"],"additional_accession":[]},"is_claimable":false,"name":"Prostate extracellular vesicles in patient plasma as a liquid biopsy platform for prostate cancer using nanoscale flow cytometry.","description":"<h4>Background</h4>Extracellular vesicles released by prostate cancer present in seminal fluid, urine, and blood may represent a non-invasive means to identify and prioritize patients with intermediate risk and high risk of prostate cancer. We hypothesize that enumeration of circulating prostate microparticles (PMPs), a type of extracellular vesicle (EV), can identify patients with Gleason Score≥4+4 prostate cancer (PCa) in a manner independent of PSA.<h4>Patients and methods</h4>Plasmas from healthy volunteers, benign prostatic hyperplasia patients, and PCa patients with various Gleason score patterns were analyzed for PMPs. We used nanoscale flow cytometry to enumerate PMPs which were defined as submicron events (100-1000nm) immunoreactive to anti-PSMA mAb when compared to isotype contro","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Feb","modification":"2025-04-06T19:16:05.2Z","creation":"2019-03-27T02:15:10Z"},"accession":"S-EPMC4891008","cross_references":{"pubmed":["26814433"],"doi":["10.18632/oncotarget.6983"]}}